GoodCap Pharmaceuticals
GoodCap Pharmaceuticals is dedicated to improving the lives of individuals suffering from neuroinflammatory diseases by developing innovative therapeutic formulations. Founded in 2018, the company focuses on addressing the root causes of psychiatric and neurodegenerative disorders, particularly PTSD, through its lead drug candidate, GCAP001.
GoodCap Pharmaceuticals
What We Do
GoodCap’s lead drug candidate, GCAP001, combines two classes of molecules that significantly reduce key inflammatory biomarkers associated with psychiatric and neurodegenerative disorders, with a focus on PTSD.
Psychological and Cognitive Health and Performance
Drugs
Key People
Darryl Hudson, PhD
Co-founder and Chief Innovation Officer
Irie Selkirk
Co-founder
Ralph Landau, PhD
Chief Science Officer
Andrew Williams, MBA
Chief Financial Officer
Theresa Matkovits, PhD
Chair of Board
News & Updates
Compositions for Reducing Inflammation to Improve or Maintain Mental or Physical Health
Patent application capturing both composition of matter and methods of use, targeting inflammation-based disease states including mood disorders, pain, digestive problems, substance abuse, and cancer.